Literature DB >> 11779347

Decay of HIV type 1 DNA and development of drug-resistant mutants in patients with primary HIV type 1 infection receiving highly active antiretroviral therapy.

E Riva1, M Pistello, P Narciso, G D'Offizi, P Isola, V Galati, O Turriziani, V Tozzi, L Vincenzi, F Dianzani, G Antonelli.   

Abstract

The present study was aimed at describing the effect of highly active antiretroviral therapy (HAART) in 10 patients with primary HIV infection (PHI). Clearance rates of HIV RNA and HIV DNA in peripheral blood as well as the preexistence and the emergence of drug-resistant strains of HIV were determined over 52 weeks of treatment. The data indicate that HAART is able to induce a suppression of plasma viral load together with a significant decrease, but not a suppression, of peripheral blood mononuclear cell-associated proviral DNA in PHI subjects. Analysis of drug-resistant strains revealed that three PHI patients, showing a complete virologic response, developed mutations in the pol gene, thus suggesting that a persistent residual virus replication exists despite a sustained suppression of plasma viremia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11779347     DOI: 10.1089/088922201753342004

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  5 in total

1.  In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA.

Authors:  Mark Sharkey; Karine Triques; Daniel R Kuritzkes; Mario Stevenson
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

2.  Splenic marginal zone lymphoma in a HIV-1 infected patient: evidence favouring a pathogenetic role of HIV-1 itself in the lymphomagenesis.

Authors:  M Cagliuso; V Conti; S Trasarti; L Lombardi; M Riminucci; M Perez; O Turriziani; F Falasca; M Nanni; A Tafuri; I Mezzaroma
Journal:  Infection       Date:  2012-09-25       Impact factor: 3.553

3.  Cellular HIV-1 DNA levels in patients receiving antiretroviral therapy strongly correlate with therapy initiation timing but not with therapy duration.

Authors:  Dai Watanabe; Shiro Ibe; Tomoko Uehira; Rumi Minami; Atsushi Sasakawa; Keishiro Yajima; Hitoshi Yonemoto; Hiroki Bando; Yoshihiko Ogawa; Tomohiro Taniguchi; Daisuke Kasai; Yasuharu Nishida; Masahiro Yamamoto; Tsuguhiro Kaneda; Takuma Shirasaka
Journal:  BMC Infect Dis       Date:  2011-05-24       Impact factor: 3.090

4.  Stability of HIV-1 Nucleic Acids in Dried Blood Spot Samples for HIV-1 Drug Resistance Genotyping.

Authors:  Susan C Aitken; Carole L Wallis; Wendy Stevens; Tobias Rinke de Wit; Rob Schuurman
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

5.  Deep sequencing of HIV-1 near full-length proviral genomes identifies high rates of BF1 recombinants including two novel circulating recombinant forms (CRF) 70_BF1 and a disseminating 71_BF1 among blood donors in Pernambuco, Brazil.

Authors:  Rodrigo Pessôa; Jaqueline Tomoko Watanabe; Paula Calabria; Alvina Clara Felix; Paula Loureiro; Ester C Sabino; Michael P Busch; Sabri S Sanabani
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.